Skip to main content

Lifeward Ltd.

corporate_fare Company Profile

Lifeward Ltd.

LFWD·NASDAQ·Industrial Applications And Services·CIK 0001607962

ReWalk is a medical device company that designs, develops, and commercializes solutions for physical rehabilitation and recovery. The company's initial product offerings were the ReWalk Personal and ReWalk Rehabilitation Exoskeleton devices, referred to as SCI Products, for individuals with spinal cord injury. These robotic exoskeletons use patented tilt-sensor technology, an onboard computer, and motion sensors to power motorized legs, enabling individuals with paraplegia to stand and walk. In March 2023, ReWalk received 510(k) clearance from the U.S. FDA for the ReWalk Personal Exoskeleton with stair and curb functionality, allowing U.S. users to navigate stairs and curbs. This feature has been available in Europe since initial CE Clearance, supported by real-world data from 47 European users over seven years, involving over 18,000 stair steps. In March 2025, the company received 510(k) clearance for the ReWalk 7 Personal Exoskeleton device, a next-generation model. ReWalk has also expanded its product offerings beyond SCI Products, including the ReStore Exo-Suit device, which began commercialization in June 2019. The ReStore is a powered, lightweight soft exo-suit designed for the rehabilitation of individuals with lower limb disabilities due to stroke. Sales of the ReStore device in the European Union ceased in May 2024.

Lifeward Ltd. (NASDAQ:LFWD) is a publicly traded company in the Industrial Applications And Services sector. Wiseek monitors LFWD SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Lifeward Executes 1-for-12 Reverse Stock Split and Boosts Authorized Shares to 100M to Meet Nasdaq Requirements
  • Lifeward Partners with Shirley Ryan AbilityLab to Boost ReWalk Exoskeleton Access
  • Director Hadar Levy Resigns from Lifeward Board Amidst Company's Ongoing Financial and Compliance Challenges
  • Lifeward Acquires IP Assets for $500K, Primarily Paid in Dilutive Shares Amidst Ongoing Strategic Shifts
  • Lifeward Secures High-Interest Bridge Loan Amidst Pending Dilutive Financing and Nasdaq Compliance Issues

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$22.03M
Net Income
-$19.91M
Diluted EPS
-$17.16
Op. Cash Flow
-$16.83M
Free Cash Flow
-$16.84M
Gross Profit
$8.43M
Operating Income
-$19.67M
Cash & Equivalents
$2.17M
Debt / Equity
0.00×
Net Margin
-90.4%
Shares Outstanding
1.52M sh
Source: 10-K · filed 2026-03-18 · accession 0001178913-26-001208
$7.29
52-week range · as of 2026-05-20 $4.14 – $15.84
Market cap
$20.52M
Volume
13.5K (1.3× avg)
3-mo avg 10K
Live data · 2026-06-03 17:24 UTC · Market open

show_chartPrice Chart

Loading chart...

feed LFWD - Filings & News (Page 2)

LFWD
Mar 02, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
8
LFWD
Mar 02, 2026, 8:15 AM EST
Source: Reuters
Importance Score:
7
LFWD
Feb 27, 2026, 4:14 PM EST
Filing Type: 8-K
Importance Score:
7
LFWD
Feb 25, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
8
LFWD
Feb 19, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
9
LFWD
Feb 09, 2026, 4:26 PM EST
Filing Type: DEFM14A
Importance Score:
9
LFWD
Feb 09, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
8
LFWD
Jan 28, 2026, 5:08 PM EST
Filing Type: PREM14A
Importance Score:
9
LFWD
Jan 28, 2026, 4:14 PM EST
Filing Type: 8-K
Importance Score:
9
LFWD
Jan 13, 2026, 8:15 AM EST
Filing Type: 8-K
Importance Score:
9
LFWD
Jan 06, 2026, 4:16 PM EST
Filing Type: 8-K
Importance Score:
8
LFWD
Jan 02, 2026, 4:16 PM EST
Filing Type: S-3/A
Importance Score:
9